Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $49.30 | Total: $246.50 |
| 1 | 10 | $41.76 | Total: $417.60 |
| 1 | 25 | $35.38 | Total: $884.50 |
| 1 | 50 | $30.16 | Total: $1,508.00 |
| 1 | 100 | $26.10 | Total: $2,610.00 |
Overview
KA2507 is a potent and selective HDAC6 inibitor with an IC50 of 2.5nM.
Chemical Properties
| Molecular Formula | C16H14N6O2 |
| Molecular Weight | 322.32 |
| CAS Numbers | 1636894-46-6 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | ONC(=O)c1ccc(CN(c2cnccn2)c2cnccn2)cc1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Apostolia M Tsimberidou, et al. Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021 May 4.